和誉-B(02256)：FGFR2/3抑制剂ABSK061治疗儿童软骨发育不全的IND获FDA许可

Core Viewpoint - The company, He Yu-B (02256), announced that its subsidiary, Shanghai He Yu Biopharmaceutical Technology Co., Ltd., has received FDA approval for the IND application of its selective small molecule FGFR2/3 inhibitor, ABSK061, aimed at treating achondroplasia in children [1] Group 1 - The IND approval from the FDA will accelerate the overseas clinical development process of ABSK061 [1] - The drug has previously been granted rare pediatric disease designation (RPDD) and orphan drug designation (ODD) by the FDA [1]